BIOMARIN PHARMACEUTICAL INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $30.06 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-26
- BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2019-03-31 was $94.55, a 183.59% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2018-03-31 was $33.34, a 7.98% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2017-03-31 was $36.23, a 13.05% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2016-03-31 was $41.67, a 25.74% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $30.06, a 16.20% decline from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $35.87, a 8.73% decline from fiscal 2023.
- BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $39.30, a 21.11% increase from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $32.45, a 2.66% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $30.06 10-K · filed 2026-02-26 | |||||
| 2024-12-31 | $35.87 10-K · filed 2026-02-26 | |||||
| 2023-12-31 | $39.30 10-K · filed 2026-02-26 | |||||
| 2022-12-31 | $32.45 10-K · filed 2025-02-24 | |||||
| 2021-12-31 | $31.61 10-K · filed 2024-02-26 | |||||
| 2020-12-31 | $27.47 10-K · filed 2023-02-27 | |||||
| 2019-12-31 | $36.84 10-K · filed 2022-02-25 | |||||
| 2019-06-30 | $94.55 10-Q · filed 2019-08-02 | |||||
| 2019-03-31 | $94.55 10-Q · filed 2019-04-29 | |||||
| 2018-12-31 | $33.40 10-K · filed 2021-02-26 | |||||
| 2018-09-30 | $33.40 10-Q · filed 2018-10-26 | |||||
| 2018-06-30 | $33.34 10-Q · filed 2018-08-03 | |||||
| 2018-03-31 | $33.34 10-Q · filed 2018-04-27 | |||||
| 2017-12-31 | $36.07 10-K · filed 2020-02-27 | |||||
| 2017-09-30 | $36.11 10-Q · filed 2017-10-31 | |||||
| 2017-06-30 | $36.02 10-Q · filed 2017-08-02 | |||||
| 2017-03-31 | $36.23 10-Q · filed 2017-05-04 | |||||
| 2016-12-31 | $40.70 10-K · filed 2019-02-28 | |||||
| 2016-09-30 | $41.15 10-Q · filed 2016-11-03 | |||||
| 2016-06-30 | $41.29 10-Q · filed 2016-08-08 | |||||
| 2016-03-31 | $41.67 10-Q · filed 2016-05-02 | |||||
| 2015-12-31 | $56.76 10-K · filed 2018-02-26 | |||||
| 2015-09-30 | $56.86 10-Q · filed 2015-11-02 | |||||
| 2015-06-30 | $56.46 10-Q · filed 2015-08-05 | |||||
| 2015-03-31 | $56.11 10-Q · filed 2015-05-05 | |||||
| 2014-12-31 | $30.93 10-K · filed 2017-02-27 | |||||
| 2014-09-30 | $30.90 10-Q · filed 2014-10-28 | |||||
| 2014-06-30 | $30.98 10-Q · filed 2014-07-31 | |||||
| 2014-03-31 | $37.44 10-Q · filed 2014-05-02 | |||||
| 2013-12-31 | $30.77 10-K · filed 2016-02-29 | |||||
| 2013-09-30 | $30.62 10-Q · filed 2013-10-28 | |||||
| 2013-06-30 | $30.45 10-Q · filed 2013-07-29 | |||||
| 2013-03-31 | $25.36 10-Q · filed 2013-04-29 | |||||
| 2012-12-31 | $16.98 10-K · filed 2015-03-02 | |||||
| 2012-09-30 | $37.35 10-Q · filed 2012-10-29 | |||||
| 2012-06-30 | $16.73 10-Q · filed 2012-08-02 | |||||
| 2011-12-31 | $27.89 10-K · filed 2014-02-26 | $13.60 10-K · filed 2012-02-22 | ||||
| 2011-09-30 | $13.49 10-Q · filed 2011-10-31 | |||||
| 2011-06-30 | $13.46 10-Q · filed 2011-08-01 | |||||
| 2011-06-01 | $32.61 10-Q · filed 2011-08-01 | |||||
| 2010-12-31 | $11.25 10-K · filed 2013-02-26 | |||||
| 2009-12-31 | $7.48 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |